In 2006, we were acquired by the Japan-based Terumo Corporation. Terumo provided the framework for MicroVention to operate autonomously and grow freely. Today, we have launched over 30 products and have expanded beyond cerebral aneurysms, to include treatment for ischemic stroke, carotid artery disease, and neurovascular malformations.

Our vision: MicroVention’s goal is to be the leading global neuroendovascular company. We will accomplish this goal by producing the most reliable, easiest to use and most technologically advanced products supported by proven clinical data. MicroVention is equally committed to providing cost efficient and accessible healthcare.

Our mission: MicroVention is to be an industry leader in the creation and commercialization of innovative neuroendovascular technologies that provide a meaningful improvement in patient lives.

MicroVention - Model LVIS & LVIS Jr - Coil Assist Stents - Brochure